Not sure he said "whatever comes first", there have been several good scientific forums in the past 6 months. His point was full, reviewed results will eventually be made public, and if journal publication was taking too long or not happening, the company would just present it. Was good to hear.
I'm confident we can produce a publishable scientific paper (we've led a couple already) from the AD trial. We are just at the mercy of top journals with competing submissions. Missling has made noises about still-undisclosed valuable results, but that remains to be seen. The 'highlights' (ie, best parts) have no doubt been disclosed already. (For the knuckleheads: remember your ADL nonsense. It's biotech, not fantasyland.)
The full results are going to be a better glimpse of what regulators will be working with, so investors are looking forward to seeing them.
Market Data 
Markets 
